RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel Genomic Alterations of Antigen & Payload Targets Mediate Polyclonal Acquired Clinical Resista…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel Genomic Alterations of Antigen & Payload Targets Mediate Polyclonal Acquired Clinical Resista…
ICYMI in @CD_AACR: Parallel Genomic Alterations of Antigen & Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-negative #BreastCancer by Leif Ellisen, @dradityabardia & colleagues https://t.co/vAOVkd
RT @ElizSMcKenna: ICYMI in @CD_AACR by Leif Ellisen, @dradityabardia and colleagues - Parallel Genomic Alterations of Antigen and Payload T…
RT @ElizSMcKenna: ICYMI in @CD_AACR by Leif Ellisen, @dradityabardia and colleagues - Parallel Genomic Alterations of Antigen and Payload T…
RT @ElizSMcKenna: ICYMI in @CD_AACR by Leif Ellisen, @dradityabardia and colleagues - Parallel Genomic Alterations of Antigen and Payload T…
ICYMI in @CD_AACR by Leif Ellisen, @dradityabardia and colleagues - Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative #BreastCancer https://t.co/vAOVkdz6I
RT @cdanicas: Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Go…
RT @cdanicas: Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Go…
RT @cdanicas: Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Go…
Yet another example of how targeted therapy is doomed to fail in the vast majority of cancers Cut it out, or radiate it. Trying to 🎯 an evolving moving target is a fools errand https://t.co/Ibc0vTB9GH
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer | Cancer Discovery | American Association for Cancer Research https://t.co/1AWp7jS6IC
RT @PTarantinoMD: @jeff7091 Still unclear. A @CD_AACR paper from 2021 suggested that it may be both due to the payload and target. https:/…
@jeff7091 Still unclear. A @CD_AACR paper from 2021 suggested that it may be both due to the payload and target. https://t.co/RJT5yJuGwR
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
I guess using Immune-based @ADC like molecules, can bypass part of the #resistance, following MoA like epitope spreading.
RT @NicoleKuderer: @OncoAlert #GenomicMedicne also helps explain key ADC Resistance @aacr Genomic alterations of antigen as well as of pa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @NicoleKuderer: @OncoAlert #GenomicMedicne also helps explain key ADC Resistance @aacr Genomic alterations of antigen as well as of pa…
RT @NicoleKuderer: @OncoAlert #GenomicMedicne also helps explain key ADC Resistance @aacr Genomic alterations of antigen as well as of pa…
@OncoAlert #GenomicMedicne also helps explain key ADC Resistance @aacr Genomic alterations of antigen as well as of payload targets mediate polyclonal acquired clinical resistance to #ADC @gary_lyman
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
RT @jsoriamd: ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payloa…
ADC are a growing & promising component of the anti-cancer armamentarium. Genomic alterations of antigen as well as of payload targets mediate polyclonal acquired clinical resistance to #ADC https://t.co/nnmgtayxLQ https://t.co/Go6PEqRrKX
RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resis…
ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in TNBC by Leif Ellisen, @ABhealer108, and colleagues @MGHCancerCenter #SABCS21 https://t.co/wlu2baC9ab
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab ... https://t.co/JkAjqPn3uw
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative #breastcancer, Leif Ellisen, @ABhealer108, et al. https://t.co/i6ARoekBF9 @MGHCancerCenter #antibodydru
RT @ElizSMcKenna: ICYMI in @CD_AACR, just mentioned by Puja Sapra @AstraZeneca at #Targets21: Parallel genomic alterations of antigen and p…
ICYMI in @CD_AACR, just mentioned by Puja Sapra @AstraZeneca at #Targets21: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in TNBC @ABhealer108 @MGHCancerCenter https://t
RT @PTarantinoMD: What mediates resistance to Sacituzumab Govitecan in mTNBC? In this interesting report, RNA&WE sequencing from TNBC pts…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resis…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resis…
RT @ElizSMcKenna: ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resis…
Fascinating escape mechanism of Saci resistance.
ICYMI in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative #breastcancer by Leif Ellisen, @ABhealer108, and colleagues #ESMO21 https://t.co/N5hS
RT @ABhealer108: Implications for therapeutic sequencing of ADCs in breast cancer, based on mechanism of resistance to antibody vs payload.…
RT @NatRevClinOncol: TROP2 T256R mutation can confer resistance to sacituzumab govitecan via defective plasma membrane localization and red…
RT @MammaryCell: Dr. Leif Ellisen and his team at @MGHCancerCenter describe parallel genomic alterations in both antibody and payload targe…
RT @ResearchWyatt: Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting sur…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ResearchWyatt: Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting sur…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @ResearchWyatt: Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting sur…
RT @ResearchWyatt: Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting sur…
RT @ResearchWyatt: Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting sur…
Pretty interesting as we consider acquired resistance mechanisms to ADCs in bladder cancer but also drugs exploiting surface molecules in prostate (e.g. PSMA). Will we see NECTIN4 or FOLH1 genomic alterations arise post-treatment in those with deep respons
Huge congratulations to Leif and @ABhealer108, their team and collaborators @MGHCancerCenter @harvardmed @broadinstitute to understand the resistance mechanism of the first approved antibody drug conjugate in TNBC patients https://t.co/g3LmHWUERV
RT @MammaryCell: Dr. Leif Ellisen and his team at @MGHCancerCenter describe parallel genomic alterations in both antibody and payload targe…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
Dr. Leif Ellisen and his team at @MGHCancerCenter describe parallel genomic alterations in both antibody and payload targets 🎯 associated with #TNBC resistance to Sacituzumab Govitecan. @CD_AACR | 📎 https://t.co/UpFx0QRum6 https://t.co/8bqNfyNqwV
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @NatRevClinOncol: TROP2 T256R mutation can confer resistance to sacituzumab govitecan via defective plasma membrane localization and red…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
TROP2 T256R mutation can confer resistance to sacituzumab govitecan via defective plasma membrane localization and reduced cell surface antibody binding: https://t.co/1qbwvNYygR #bcsm #blcsm #medonc #breastcancer
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
RT @getz_lab: Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCen…
Excited for the latest paper from our @IBMResearch #collaboration on #CancerResistance! Fantastic work based in @MGHCancerCenter labs of Leif Ellisen and @ABhealer108 on acquired #genomic resistance to SG therapy in triple-negative #breastcancer. @LaxmiPar
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
RT @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab gov…
Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer https://t.co/2dCWN0ulS8
RT @ElizSMcKenna: ⭐️Now online in @CD_AACR: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinica…